Research analysts at StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. The business has a 50-day moving average price of $0.14. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $8.45.
Nabriva Therapeutics Company Profile
See Also
- Five stocks we like better than Nabriva Therapeutics
- Election Stocks: How Elections Affect the Stock Market
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Progress Software Stock Back in the Green After Beating Forecasts
- About the Markup Calculator
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.